Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease.
- DOI
- 10.1007/s00330-026-12875-z
- Published
- 2026-09-16
- Container
- Eur Radiol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00330-026-12875-z,
title = {Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease.},
author = {Kleiburg F and Heijmen L and Witteveen A and van Duuren K and Zuidgeest P and Smit F and de Geus-Oei LF and van der Hulle T.},
year = {2026},
journal = {Eur Radiol},
doi = {10.1007/s00330-026-12875-z},
url = {https://doi.org/10.1007/s00330-026-12875-z}
}RIS
TY - JOUR TI - Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease. AU - Kleiburg F AU - Heijmen L AU - Witteveen A AU - van Duuren K AU - Zuidgeest P AU - Smit F AU - de Geus-Oei LF AU - van der Hulle T. PY - 2026 JO - Eur Radiol DO - 10.1007/s00330-026-12875-z UR - https://doi.org/10.1007/s00330-026-12875-z ER -
APA
F, K., L, H., A, W., K, V. D., P, Z., F, S., LF, D. G., & T., V. D. H. (2026). Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease.. Eur Radiol. https://doi.org/10.1007/s00330-026-12875-z
Source records
- europe-pmc · retrieved 2026-09-26T00:36:09.314Z